Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 13/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467613 | 0.86 | ITK (0.49) | ITKIRAK4KCNH2MAP2K2MAP2K1 | |
| SCHEMBL6466511 | 0.80 | ITK (0.44) | ITKIRAK4PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL6506908 | 0.80 | ITK (0.42) | ITKIRAK4PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL6506387 | 0.79 | ITK (0.41) | ITKIRAK4ALDH1A1MEN1POLB | |
| SCHEMBL6470449 | 0.79 | ITK (0.42) | ITKIRAK4PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL6470657 | 0.79 | ITK (0.48) | ITKIRAK4PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL6467428 | 0.78 | ITK (0.47) | ITKIRAK4ALDH1A1MEN1KMT2A | |
| SCHEMBL6468749 | 0.77 | ITK (0.44) | ITKIRAK4ALDH1A1MEN1POLB | |
| SCHEMBL6501912 | 0.77 | ITK (0.52) | ITKIRAK4PARP1L3MBTL1 | |
| SCHEMBL6465833 | 0.75 | ALDH1A1 (0.53) | ITKIRAK4PARP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | ITK 4236/4885IRAK4 27/4885PARP1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.